<div id="readability-page-1"><p><span>Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report)</span> had its target price lowered by Stifel Nicolaus  from $55.00 to $48.00 in a note issued to investors on Friday,Benzinga reports. The brokerage currently has a &#34;buy&#34; rating on the stock. Stifel Nicolaus' target price points to a potential upside of 93.22% from the company's current price.</p><ul><li>Beam Therapeutics Bolts Higher on Gene Therapy Licensing Payments</li></ul><p>Several other research analysts have also commented on the company. William Blair  reissued an &#34;outperform&#34; rating on shares of Apellis Pharmaceuticals in a report on Monday. Weiss Ratings  reissued a &#34;sell (d)&#34; rating on shares of Apellis Pharmaceuticals in a research note on Monday. The Goldman Sachs Group cut Apellis Pharmaceuticals from a &#34;neutral&#34; rating to a &#34;sell&#34; rating and cut their price objective for the stock from $26.00 to $18.00 in a report on Friday, September 26th. Mizuho decreased their price objective on Apellis Pharmaceuticals from $24.00 to $19.00 and set a &#34;neutral&#34; rating on the stock in a report on Monday, November 3rd. Finally, TD Cowen decreased their target price on shares of Apellis Pharmaceuticals from $50.00 to $45.00 and set a &#34;buy&#34; rating on the stock in a research report on Friday, October 31st. Eleven equities research analysts have rated the stock with a Buy rating, seven have assigned  a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of &#34;Hold&#34; and a consensus price target of $33.94.</p><p><b>View Our Latest Research Report on APLS</b></p><h2>Apellis Pharmaceuticals Stock Down 1.4%</h2><ul><li>Are Small Caps a Harbinger of Market Declines?</li></ul><p>APLS stock opened at $24.84 on Friday. The company has a market capitalization of $3.14 billion, a price-to-earnings ratio of 78.97 and a beta of 0.37. Apellis Pharmaceuticals has a fifty-two week low of $16.10 and a fifty-two week high of $35.57. The company has a debt-to-equity ratio of 0.90, a quick ratio of 3.10 and a current ratio of 3.54. The stock has a fifty day moving average of $23.05 and a 200-day moving average of $22.56. </p><p>Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last posted its earnings results on Thursday, October 30th. The company reported $1.67 earnings per share for the quarter, topping the consensus estimate of $1.03 by $0.64. Apellis Pharmaceuticals had a net margin of 4.43% and a return on equity of 18.94%. The firm had revenue of $458.58 million during the quarter, compared to the consensus estimate of $364.58 million. During the same quarter last year, the company earned ($0.46) earnings per share. The company's revenue was up 133.0% on a year-over-year basis.  As a group, equities research analysts predict that  Apellis Pharmaceuticals will post -1.7 earnings per share for the current year. </p><h2>Insider Buying and Selling at Apellis Pharmaceuticals</h2><p>In related news, CFO Timothy Eugene Sullivan sold 10,000 shares of Apellis Pharmaceuticals stock in a transaction on Tuesday, October 21st. The stock was sold at an average price of $28.03, for a total transaction of $280,300.00. Following the transaction, the chief financial officer directly owned 110,936 shares in the company, valued at approximately $3,109,536.08. The trade was a 8.27% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is accessible through the SEC website. Also, General Counsel David O. Watson sold 5,000 shares of the business's stock in a transaction that occurred on Tuesday, December 16th. The shares were sold at an average price of $24.49, for a total value of $122,450.00. Following the transaction, the general counsel owned 103,730 shares of the company's stock, valued at approximately $2,540,347.70. This trade represents a 4.60% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 56,092 shares of company stock valued at $1,366,652. Insiders own  6.50% of the company's stock. </p><h2>Institutional Investors Weigh In On Apellis Pharmaceuticals</h2><p>Institutional investors have recently bought and sold shares of the business. Parallel Advisors LLC raised its position in shares of  Apellis Pharmaceuticals by 80.0% during the second quarter. Parallel Advisors LLC now owns 1,924 shares of the company's stock valued at $33,000 after buying an additional 855 shares during the last quarter.  Jones Financial Companies Lllp increased its position in shares of  Apellis Pharmaceuticals by 206.8% during the 3rd quarter. Jones Financial Companies Lllp now owns 2,037 shares of the company's stock valued at $46,000 after purchasing an additional 1,373 shares during the last quarter.  Osaic Holdings Inc. raised its stake in shares of  Apellis Pharmaceuticals by 141.2% in the second quarter. Osaic Holdings Inc. now owns 2,682 shares of the company's stock valued at $47,000 after acquiring an additional 1,570 shares during the period.  Allworth Financial LP boosted its position in shares of  Apellis Pharmaceuticals by 64.1% during the third quarter. Allworth Financial LP now owns 2,194 shares of the company's stock valued at $50,000 after buying an additional 857 shares during the period.  Finally, Quantbot Technologies LP purchased a new stake in  Apellis Pharmaceuticals in the third quarter worth $64,000. Hedge funds and other institutional investors own  96.29% of the company's stock. </p><h2>About Apellis Pharmaceuticals</h2> (Get Free Report)<p>Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).</p><h2>See Also</h2><ul><li>Five stocks we like better than Apellis Pharmaceuticals</li><li>5 Top Rated Dividend Stocks to Consider</li><li>Rocket Lab's Sharp Rebound: What's Behind the Recent Momentum</li><li>The How And Why of Investing in Oil Stocks</li><li>Jabil Is Flying Under the Radar—But a 50% Surge May Be Coming</li><li>Consumer Discretionary Stocks Explained</li><li>Qualcomm’s Monster Rally Has a Catch—Can the Stock Keep Climbing?</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVBMUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVBMUw"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Apellis Pharmaceuticals Right Now?</h2><p>Before you consider Apellis Pharmaceuticals, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Apellis Pharmaceuticals wasn't on the list.</p><p>While Apellis Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

APLS

<p>Stifel Nicolaus lowered its price target for Apellis Pharmaceuticals from $55 to $48, maintaining a "buy" rating. The stock has a potential upside of 93.22% from its current price. Other analysts have mixed ratings, with a consensus "Hold" rating and a price target of $33.94. Apellis reported strong earnings, with revenue up 133% year-over-year. Insider trading activity includes significant stock sales by the CFO and General Counsel.</p>

Stifel Nicolaus Cuts Apellis Pharmaceuticals (NASDAQ:APLS) Price Target to $48.00